Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in the PROTECT-AF and PREVAIL studies, reduced risk of atrial fibrillation driven stroke, by excluding the left atrial appendage form systemic circulation.  Both studies used post procedure standardized protocols involving followup at 45 days and 6 months, imaging, and<a href="https://solaci.org/en/2022/07/15/antithrombotic-therapy-post-percutaneous-left-atrial-appendage-closure/" title="Read more" >...</a>

SOLACI Present at the Main Interventional Cardiology Meetings in the World

Once more, the Latin American Society of Interventional Cardiology (SOLACI) will attend two of the most important annual meetings in the field: the EuroPCR 2022 and the SCAI 2022 Scientific Sessions. The society will take part in with 2 challenging joint sessions to shar the Latin American reality in different areas of interest within the<a href="https://solaci.org/en/2022/05/16/solaci-present-at-the-main-interventional-cardiology-meetings-in-the-world/" title="Read more" >...</a>

Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?

Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding. One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed. Researchers conducted an analysis of the National<a href="https://solaci.org/en/2022/04/25/should-we-use-left-atrial-appendage-occlusion-more-frequently-what-real-life-data-are-available/" title="Read more" >...</a>

Bifurcación de tronco de coronaria distal: cantidad de stents

Wire Jailing at Side Branch to Prevent Occlusion After Main Vessel Stenting: Should It Be the Standard of Care?

While the ideal treatment for coronary bifurcation is provisional stenting, this can be associated with side branch occlusion, which leads to severe adverse events. To prevent this complication, several treatments have been proposed. One of them is wire jailing at side branch before stent implantation in the main vessel. However, the actual benefit of this<a href="https://solaci.org/en/2022/03/29/wire-jailing-at-side-branch-to-prevent-occlusion-after-main-vessel-stenting-should-it-be-the-standard-of-care/" title="Read more" >...</a>

revascularizacion incompleta en cirugia no cardiaca

Best Revascularization Strategy in Patients with Left Ventricular Deterioration

Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy.  According to this recent analysis of the SCAAR registry published in the European Heart Journal, long term followup seems to justify taking a higher risk initially, higher risk being myocardial revascularization surgery (CABG). The study looked at<a href="https://solaci.org/en/2021/08/11/best-revascularization-strategy-in-patients-with-left-ventricular-deterioration/" title="Read more" >...</a>

DAPT vs. Monotherapy: The Dilemma Remains After Surgery

Patients who undergo myocardial revascularization surgery and are discharged on dual antiplatelet therapy (DAPT)—aspirin plus clopidogrel—have a lower risk of major cardiovascular and cerebral events than patients on aspirin monotherapy. Furthermore, the risk of bleeding is not increased for those receiving DAPT. This information comes from a registry of over 18,000 patients recently published in the<a href="https://solaci.org/en/2021/06/09/dapt-vs-monotherapy-the-dilemma-remains-after-surgery/" title="Read more" >...</a>

Luz roja para el TAVI en pacientes de bajo riesgo

Unilateral Vascular Access in TAVR: Our Main Procedure, Increasingly Minimalist

There has been a significant decline in vascular complications in the last few years due to improvements in device profiles and operator experience on transcatheter aortic valve replacement (TAVR). Unilateral vascular access for transfemoral TAVR is as safe as bilateral access and it could be more comfortable for patients according to this study recently published<a href="https://solaci.org/en/2019/12/08/unilateral-vascular-access-in-tavr-our-main-procedure-increasingly-minimalist/" title="Read more" >...</a>

ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective

This is a sub-study of the THEMIS presented during the ESC 2019 scientific sessions in Paris, and simultaneously published in Lancet. They were all diabetics with stable coronary artery disease, but in this sub-study patients also had prior PCI. It included over 11000 patients with prior PCI for whom the combination of ticagrelor and aspirin<a href="https://solaci.org/en/2019/09/03/esc-2019-themis-pci-unlike-in-the-main-study-here-ticagrelor-is-indeed-effective/" title="Read more" >...</a>

Dr. Mario Araya Presents the Main Attractions of this Year’s SOLACI Sessions

SOLACI-SBHCI 2019 has come to an end, but SOLACI’s schedule will stay tight until the end of the year. In fact, we are getting closer and closer to Bolivia Sessions 2019 (August 23 – 24 in Cochabamba, Bolivia), Panama Sessions 2019 (September 19 thru 21 in Panama), and Ecuador Sessions 2019 (October 11 – 12 in Manta, Ecuador). That<a href="https://solaci.org/en/2019/08/13/dr-mario-araya-presents-the-main-attractions-of-this-years-solaci-sessions/" title="Read more" >...</a>

Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?

After post TAVR mean 3-year follow-up, a new onset persistent left bundle branch block (LBBB) was not associated with higher mortality or hospitalization for cardiac failure according to this study to be published soon in J Am Coll Cardiol Intv. Nevertheless, LBBB was associated to higher risk of definite pacemaker and a negative impact in<a href="https://solaci.org/en/2019/06/05/post-tavr-new-onset-left-bundle-branch-block-at-long-term-worth-our-attention/" title="Read more" >...</a>

left main